USE - For the treatment and/or prophylaxis of a condition associated with the virus, or the condition optionally being a disease condition. Also for the treatment of a condition associated with a DNA virus selected from order Caudovirales, including families Myoviridae, Podoviridae, Siphoviridae; order Herpesvirales, including families Alloherpesvirdae, Herpersviridae, and Malacoherpesviridae; order Ligamenvirales, including families Lipothrixviridae, and Rudiviridae; and families Adenovirdae, Ampullaviridae, Ascoviridae, Asfarviridae, Baculoviridae, Bicaudaviridae, Clavaviridae, Corticoviridae, Fuselloviridae, Globuloviridae, Guttaviridae, Hytrosaviridae, Iridoviridae, Miminviridae, Nimaviridae, Papillomaviridae, Phycodnaviridae, Plasmaviridae, Polydnaviruses, Polyomaviridae, Poxviridae, and Tectiviridae (preferably Herpesvirales, especially Herpesviridae, and the virus is herpes simplex virus type 1, or HSVI). The virus is an avirulent form selected from replication-deficient forms of the virus, attenuated forms of the virus, and forms of the virus modified, to prevent integration of the viral genome into the host genome (claimed). ADVANTAGE - The HIV1 Tat expressed by replication-competent HSV1 vectors not only does not dysregulate the immune system against HSV infection, but increases and broadens the Th1-like and CTL responses against HSV1 immunodominant and subdominant T cell epitopes, as well as eliciting detectable immunoglobulin G (IgG) responses. A similar attenuated HSV1 recombinant vector without Tat (HSV1-LacZ) induces lower T cell responses, which are directed only against the immunodominant epitopes, and fails to generate measurable IgG serum responses. Immunization with the present vaccines is effective, and the present vaccines are capable of protecting BALB/c and C57BL/6 mice against HSV lesions and death after challenge with a lethal dose of wild type HSV1 virus.
Use of replication deficient hsv-1 as a vaccine vector for the deli vary of hiv-1 tat antigen
MARCONI Peggy Carla Raffaella;CAPUTO Antonella;GAVIOLI Riccardo;MANSERVIGI Roberto
2013
Abstract
USE - For the treatment and/or prophylaxis of a condition associated with the virus, or the condition optionally being a disease condition. Also for the treatment of a condition associated with a DNA virus selected from order Caudovirales, including families Myoviridae, Podoviridae, Siphoviridae; order Herpesvirales, including families Alloherpesvirdae, Herpersviridae, and Malacoherpesviridae; order Ligamenvirales, including families Lipothrixviridae, and Rudiviridae; and families Adenovirdae, Ampullaviridae, Ascoviridae, Asfarviridae, Baculoviridae, Bicaudaviridae, Clavaviridae, Corticoviridae, Fuselloviridae, Globuloviridae, Guttaviridae, Hytrosaviridae, Iridoviridae, Miminviridae, Nimaviridae, Papillomaviridae, Phycodnaviridae, Plasmaviridae, Polydnaviruses, Polyomaviridae, Poxviridae, and Tectiviridae (preferably Herpesvirales, especially Herpesviridae, and the virus is herpes simplex virus type 1, or HSVI). The virus is an avirulent form selected from replication-deficient forms of the virus, attenuated forms of the virus, and forms of the virus modified, to prevent integration of the viral genome into the host genome (claimed). ADVANTAGE - The HIV1 Tat expressed by replication-competent HSV1 vectors not only does not dysregulate the immune system against HSV infection, but increases and broadens the Th1-like and CTL responses against HSV1 immunodominant and subdominant T cell epitopes, as well as eliciting detectable immunoglobulin G (IgG) responses. A similar attenuated HSV1 recombinant vector without Tat (HSV1-LacZ) induces lower T cell responses, which are directed only against the immunodominant epitopes, and fails to generate measurable IgG serum responses. Immunization with the present vaccines is effective, and the present vaccines are capable of protecting BALB/c and C57BL/6 mice against HSV lesions and death after challenge with a lethal dose of wild type HSV1 virus.File | Dimensione | Formato | |
---|---|---|---|
GB201301119 D0.pdf
solo gestori archivio
Tipologia:
Altro materiale allegato
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
187.11 kB
Formato
Adobe PDF
|
187.11 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.